Pipeline Insight: Insomnia - Targeting the sleep maintenance market

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2007-04-12

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The launch of serotonin antagonists which are largely aimed at treating sleep maintenance is set to make a substantial impact on the insomnia market, which will increase in value across the seven major markets from $6.1 billion in 2006 to $7.7 billion in 2016.


Scope

  • Analysis of patient potential, unmet needs and clinical trial design in insomnia
  • Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline
  • Detailed profiles of key compounds in development for use in insomnia, with forecasts of drug revenues to 2016
  • Discussion of Sanofi-Aventis' and Neurocrine's strategies, and insight from key industry opinion leaders


    • Report Highlights
    Serotonin receptor antagonists are the most prevalent drug class in the late-stage insomnia pipeline. This represents a move away from the GABA agonists which currently dominate the market. Datamonitor predicts that serotonin antagonist companies will be important players in the market in the future, led by Sanofi-Aventis' eplivanserin.

    The majority of pipeline drugs are being investigated for sleep maintenance as opposed to sleep onset insomnia and there is a trend towards the development of drugs for the treatment of co-morbid disorders.

    In March 2007, Merck & Co. and Lundbeck discontinued development of their Phase III drug, gaboxadol, due to disappointing trial results. Although this is a considerable blow to Lundbeck, the reduction in competition is positive news for current and future insomnia market players.


    Reasons to Purchase

  • Understand unmet needs in the insomnia market based on key opinion leader comments
  • Benchmark key late-stage insomnia compounds against current market leaders
  • Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: insomnia sleep disorders eplivanserin insomnia pipeline pd200390 market stage silenor late datamonitor sleep

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.